Media

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oncopeptides publishes Q3 report 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Vicore Pharma – Interim report July-September 2024

Oncopeptides – Invitation to presentation of the Q3 report 2024

Carisma Therapeutics Announces Changes to its Board of Directors

Pulmonx Reports Third Quarter 2024 Financial Results

SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial

Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)